Surprising Analyst 12-Month Target For PABU
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 30 2025
0mins
Source: NASDAQ.COM
ETF Performance Analysis: The iShares Paris-Aligned Climate MSCI USA ETF (PABU) has an implied analyst target price of $74.02, indicating a potential upside of 12.66% from its current trading price of $65.70.
Stock Specific Upside Potential: Notable underlying holdings like Healthpeak Properties Inc, AMETEK Inc, and The Trade Desk Inc show significant upside potential based on average analyst target prices, raising questions about the validity of these targets amidst market developments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DOC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DOC
Wall Street analysts forecast DOC stock price to fall
12 Analyst Rating
6 Buy
6 Hold
0 Sell
Moderate Buy
Current: 20.500
Low
16.71
Averages
19.23
High
21.00
Current: 20.500
Low
16.71
Averages
19.23
High
21.00
About DOC
Healthpeak Properties, Inc. is a fully integrated real estate investment trust (REIT). The Company acquires, develops, owns, leases, and manages healthcare real estate across the United States. It owns, operates, and develops real estate focused on healthcare discovery and delivery. The Company operates through three segments: outpatient medical, lab, and senior housing. Its outpatient medical and lab segments own, operates, and develops outpatient medical buildings, hospitals, and lab buildings. Its portfolio includes Baylor Scott & White Charles A. Sammons Cancer Center, 8 C1TY Blvd, The Boardwalk, Springwoods Outpatient Medical Facility: St Luke’s Health – Springwoods Village, Vantage, UF Health North Medical Building, Avondale Outpatient Medical Facility, Wesley Chapel Medical Building II: AdventHealth Wesley Chapel, Cambridge Discovery Park, and others. The Company owns approximately 700 properties nationwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Morgan Stanley Downgrades Life Sciences REITs Amid Market Uncertainty
- Rating Downgrade: Morgan Stanley downgraded Healthpeak Properties (DOC) from Overweight to Equal-weight, although the price target was raised from $20 to $22, indicating confidence in its strong senior housing, yet limited visibility on overall market recovery may hinder future growth.
- Market Pressure: Alexandria Real Estate Equities (ARE) was downgraded to Underweight, with analysts noting that despite some constructive leasing data, the Q1 performance still showed near-term pressure, reflecting uncertainty in market demand.
- Stock Price Reaction: During pre-market trading on Friday, DOC's stock fell 1.02% to $20.29, while ARE's stock decreased by 0.17% to $52.68, indicating market sensitivity to the rating changes.
- Future Outlook: Morgan Stanley stated that Healthpeak Properties' outlook would improve if lab market trends exceed the 3% to 4% estimates, while ARE needs tenant demand to convert into signed leases to stabilize occupancy and enhance same-store net operating income.
See More
Healthpeak Properties Dividend Outlook
- Dividend Volatility: Healthpeak Properties Inc's dividend amounts are influenced by the company's profitability fluctuations, and historical data indicates uncertainty regarding the sustainability of its dividends, prompting investors to assess future earnings cautiously.
- Annual Yield Expectations: While the current market anticipates a 6% annual yield for Healthpeak, actual returns may vary due to profitability instability, necessitating investor attention to the company's financial performance.
- Historical Data Reference: By analyzing Healthpeak's historical dividend chart, investors can better judge whether the recent dividend is likely to continue, enabling more informed investment decisions.
- Market Dynamics Impact: Fluctuations in market demand for dividend stocks may affect Healthpeak's dividend policy, and investors should monitor market trends and changes in the company's profitability to evaluate future dividend payment capabilities.
See More
Diversified Healthcare Shares Surge 5.9% Amid Positive Outlook
- Stock Price Surge: Diversified Healthcare (DHC) shares rose 5.9% in the last trading session to close at $8.79, with notable trading volume exceeding typical levels, reflecting increased investor optimism despite a 1.4% decline over the past four weeks.
- Financial Expectations: The upcoming quarterly report is expected to show FFO of $0.14 per share, representing a 75% year-over-year increase, while revenues are projected at $383.19 million, up 0.1% from the previous year, indicating the company's potential for growth in a stable operating environment.
- Estimate Revision Trends: While FFO and revenue growth expectations are crucial for assessing stock potential, empirical research indicates a strong correlation between trends in FFO estimate revisions and near-term stock price movements, making it essential for investors to monitor any changes in DHC's FFO estimates.
- Market Ranking: DHC currently holds a Zacks Rank of 3 (Hold), reflecting a cautious market sentiment regarding its future performance, prompting investors to closely watch its subsequent developments to determine if the stock can maintain its upward trajectory.
See More
Healthpeak Properties Q1 2026 Earnings Call Highlights
- Acquisition Opportunity: Healthpeak completed a once-in-a-decade acquisition at the Gateway campus in South San Francisco, signing 62,000 square feet of leases, which indicates strong leasing momentum and is expected to enhance future revenues and market positioning.
- IPO Proceeds: The company successfully completed the IPO of its senior housing business in March, with expected proceeds adding approximately $0.04 per share to earnings, thereby enhancing financial stability and investor confidence.
- Stock Buyback: Healthpeak repurchased $100 million of stock in April at a yield exceeding 10%, which not only boosted earnings per share expectations but also supported guidance for 2026 earnings.
- Financial Outlook: The company raised its 2026 adjusted FFO guidance to a range of $1.71 to $1.75 per share, reflecting strong operational performance and market demand, despite facing refinancing pressures and tenant exit risks.
See More
Significant Stock Price Movements for Multiple Companies
- Arm Holdings Surge: Ahead of its earnings report, Arm Holdings saw a nearly 13% jump on Nasdaq, with UBS analyst raising its 12-month price target from $175 to $245, indicating strong market optimism for its growth potential.
- Healthpeak Properties Strong Performance: The healthcare REIT soared 18% after first-quarter funds from operations and revenue exceeded Wall Street expectations, raising its second-quarter FFO guidance to $1.71 to $1.75, reflecting robust business momentum.
- CDW Stock Decline: CDW shares dropped 19% after reporting disappointing operating income in Q1, with adjusted EPS of $2.28 matching consensus, yet the company reaffirmed its 2026 outlook, raising concerns about future performance.
- Aurora Innovation Partnership: Aurora Innovation's stock rose 9% following a deal to provide driverless technology to Berkshire Hathaway's McLane, which is expected to enhance its competitive edge in the long-haul trucking market.
See More
Healthpeak Properties Q1 Beats Estimates, Raises Full-Year Guidance
- Earnings Beat: Healthpeak Properties reported Q1 adjusted FFO of $0.45, surpassing the $0.43 consensus, although it declined from $0.47 in Q4 2025, indicating resilience amid market fluctuations.
- Revenue Growth: Q1 revenue reached $753 million, exceeding the $693.1 million forecast, and increased from $719.4 million in the previous quarter and $702.9 million a year ago, reflecting strong performance in the healthcare real estate sector.
- Successful IPO: During the quarter, Healthpeak completed the IPO of Janus Living, generating approximately $880 million in net proceeds, showcasing the company's strong appeal in the capital markets and investor confidence.
- Leasing Activity: Outpatient medical and lab new and renewal lease executions totaled 1.2 million square feet, with renewal cash releasing spreads at 5.4%, demonstrating the company's stability and growth potential in the leasing market.
See More
Morgan Stanley Downgrades Life Sciences REITs Amid Market Uncertainty
- Rating Downgrade: Morgan Stanley downgraded Healthpeak Properties (DOC) from Overweight to Equal-weight, although the price target was raised from $20 to $22, indicating confidence in its strong senior housing, yet limited visibility on overall market recovery may hinder future growth.
- Market Pressure: Alexandria Real Estate Equities (ARE) was downgraded to Underweight, with analysts noting that despite some constructive leasing data, the Q1 performance still showed near-term pressure, reflecting uncertainty in market demand.
- Stock Price Reaction: During pre-market trading on Friday, DOC's stock fell 1.02% to $20.29, while ARE's stock decreased by 0.17% to $52.68, indicating market sensitivity to the rating changes.
- Future Outlook: Morgan Stanley stated that Healthpeak Properties' outlook would improve if lab market trends exceed the 3% to 4% estimates, while ARE needs tenant demand to convert into signed leases to stabilize occupancy and enhance same-store net operating income.
See More
Healthpeak Properties Dividend Outlook
- Dividend Volatility: Healthpeak Properties Inc's dividend amounts are influenced by the company's profitability fluctuations, and historical data indicates uncertainty regarding the sustainability of its dividends, prompting investors to assess future earnings cautiously.
- Annual Yield Expectations: While the current market anticipates a 6% annual yield for Healthpeak, actual returns may vary due to profitability instability, necessitating investor attention to the company's financial performance.
- Historical Data Reference: By analyzing Healthpeak's historical dividend chart, investors can better judge whether the recent dividend is likely to continue, enabling more informed investment decisions.
- Market Dynamics Impact: Fluctuations in market demand for dividend stocks may affect Healthpeak's dividend policy, and investors should monitor market trends and changes in the company's profitability to evaluate future dividend payment capabilities.
See More
Diversified Healthcare Shares Surge 5.9% Amid Positive Outlook
- Stock Price Surge: Diversified Healthcare (DHC) shares rose 5.9% in the last trading session to close at $8.79, with notable trading volume exceeding typical levels, reflecting increased investor optimism despite a 1.4% decline over the past four weeks.
- Financial Expectations: The upcoming quarterly report is expected to show FFO of $0.14 per share, representing a 75% year-over-year increase, while revenues are projected at $383.19 million, up 0.1% from the previous year, indicating the company's potential for growth in a stable operating environment.
- Estimate Revision Trends: While FFO and revenue growth expectations are crucial for assessing stock potential, empirical research indicates a strong correlation between trends in FFO estimate revisions and near-term stock price movements, making it essential for investors to monitor any changes in DHC's FFO estimates.
- Market Ranking: DHC currently holds a Zacks Rank of 3 (Hold), reflecting a cautious market sentiment regarding its future performance, prompting investors to closely watch its subsequent developments to determine if the stock can maintain its upward trajectory.
See More
Healthpeak Properties Q1 2026 Earnings Call Highlights
- Acquisition Opportunity: Healthpeak completed a once-in-a-decade acquisition at the Gateway campus in South San Francisco, signing 62,000 square feet of leases, which indicates strong leasing momentum and is expected to enhance future revenues and market positioning.
- IPO Proceeds: The company successfully completed the IPO of its senior housing business in March, with expected proceeds adding approximately $0.04 per share to earnings, thereby enhancing financial stability and investor confidence.
- Stock Buyback: Healthpeak repurchased $100 million of stock in April at a yield exceeding 10%, which not only boosted earnings per share expectations but also supported guidance for 2026 earnings.
- Financial Outlook: The company raised its 2026 adjusted FFO guidance to a range of $1.71 to $1.75 per share, reflecting strong operational performance and market demand, despite facing refinancing pressures and tenant exit risks.
See More
Significant Stock Price Movements for Multiple Companies
- Arm Holdings Surge: Ahead of its earnings report, Arm Holdings saw a nearly 13% jump on Nasdaq, with UBS analyst raising its 12-month price target from $175 to $245, indicating strong market optimism for its growth potential.
- Healthpeak Properties Strong Performance: The healthcare REIT soared 18% after first-quarter funds from operations and revenue exceeded Wall Street expectations, raising its second-quarter FFO guidance to $1.71 to $1.75, reflecting robust business momentum.
- CDW Stock Decline: CDW shares dropped 19% after reporting disappointing operating income in Q1, with adjusted EPS of $2.28 matching consensus, yet the company reaffirmed its 2026 outlook, raising concerns about future performance.
- Aurora Innovation Partnership: Aurora Innovation's stock rose 9% following a deal to provide driverless technology to Berkshire Hathaway's McLane, which is expected to enhance its competitive edge in the long-haul trucking market.
See More
Healthpeak Properties Q1 Beats Estimates, Raises Full-Year Guidance
- Earnings Beat: Healthpeak Properties reported Q1 adjusted FFO of $0.45, surpassing the $0.43 consensus, although it declined from $0.47 in Q4 2025, indicating resilience amid market fluctuations.
- Revenue Growth: Q1 revenue reached $753 million, exceeding the $693.1 million forecast, and increased from $719.4 million in the previous quarter and $702.9 million a year ago, reflecting strong performance in the healthcare real estate sector.
- Successful IPO: During the quarter, Healthpeak completed the IPO of Janus Living, generating approximately $880 million in net proceeds, showcasing the company's strong appeal in the capital markets and investor confidence.
- Leasing Activity: Outpatient medical and lab new and renewal lease executions totaled 1.2 million square feet, with renewal cash releasing spreads at 5.4%, demonstrating the company's stability and growth potential in the leasing market.
See More
